|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
L01EL01
|
|
gptkbp:blackBoxWarning
|
none
|
|
gptkbp:brand
|
gptkb:Imbruvica
|
|
gptkbp:CASNumber
|
936563-96-1
|
|
gptkbp:category
|
protease inhibitor
antineoplastic agent
orphan drug
|
|
gptkbp:chemicalFormula
|
C25H24N6O2
|
|
gptkbp:contraindication
|
hypersensitivity to ibrutinib
|
|
gptkbp:developer
|
gptkb:Janssen_Biotech
gptkb:Pharmacyclics
|
|
gptkbp:drugInteraction
|
CYP3A inducers
CYP3A inhibitors
|
|
gptkbp:eliminationHalfLife
|
4-6 hours
|
|
gptkbp:firstApprovalAgency
|
gptkb:FDA
|
|
gptkbp:form
|
gptkb:tablet
capsule
oral suspension
|
|
gptkbp:genericName
|
gptkb:ibrutinib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Imbruvica
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Janssen
gptkb:AbbVie
|
|
gptkbp:mechanismOfAction
|
Bruton's tyrosine kinase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patent
|
gptkb:Janssen_Biotech
gptkb:Pharmacyclics
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:prescribes
|
adults
pediatric patients (in some indications)
|
|
gptkbp:proteinBinding
|
97.3%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:atrial_fibrillation
nausea
diarrhea
bleeding
fatigue
hypertension
|
|
gptkbp:status
|
approved
|
|
gptkbp:usedFor
|
gptkb:mantle_cell_lymphoma
gptkb:Waldenström's_macroglobulinemia
gptkb:chronic_graft_versus_host_disease
gptkb:marginal_zone_lymphoma
chronic lymphocytic leukemia
|
|
gptkbp:bfsParent
|
gptkb:AbbVie
|
|
gptkbp:bfsLayer
|
6
|